A post hoc analysis found similar safety outcomes for fixed-duration regimens containing acalabrutinib/venetoclax across age groups in treatment-naive CLL.
|Podcasts|August 8, 2018
Advanced Non-Small Cell Lung Cancer Meeting in Denver
Author(s)Onclive Team
We went out to Denver, Colorado for a State of the Science Summit on Advanced Non–Small Cell Lung Cancer. The conference spanned screening, molecular profiling, early-stage advances, treatment for oncogenic-driven advanced disease, and immunotherapy.
Advertisement
We went out to Denver, Colorado for a State of the Science Summit on Advanced Non—Small Cell Lung Cancer. The conference spanned screening, molecular profiling, early-stage advances, treatment for oncogenic-driven advanced disease, and immunotherapy.
Advertisement
Related to this article
Mayo Clinic researchers identified a protein that cancer cells use to shut down the body's immune response, which may help develop novel cancer treatments.
T-DXd plus pertuzumab was approved in China as first-line treatment for unresectable or metastatic HER2-positive breast cancer.
Topline phase 2a data showed a 48.9% six-month progression-free survival rate with intranasal NEO100 in previously treated IDH1-mutant glioma.
Komal Jhaveri, MD, FACP, discusses the role of CDK4/6 inhibitors for patients with hormone receptor–positive disease and how oral SERD use is changing.
Jorge Cortes, MD, discusses the FDA approval of orally disintegrating nilotinib tablets for patients with chronic myeloid leukemia.
PDS Biotechnology will prioritize the IL-12 immunocytokine PDS0301 in metastatic colorectal cancer and pursue a partnership strategy for PDS0101.
Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
Advertisement
Advertisement
Trending on OncLive
1
Phase 3 VERSATILE-003 Trial of PDS0101 in HNSCC Is Discontinued
2
CD24 Expression Confers Resistance to Anti–PD-1 Therapy in NSCLC, RET-TKI Dose Reductions Do Not Compromise Outcomes in RET+ Disease
3
FDA Advisory Committee to Review Premarket Approval Application for Multi-Cancer Early Detection Test
4
Dr Silverstein on the Efficacy of Abemaciclib and Hormonal Therapy in Recurrent Ovarian and Endometrial Cancer
5